NCT00330759View on ClinicalTrials.gov

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

PHASE3CompletedINTERVENTIONAL

Enrollment

1,779

Participants

Timeline

Start Date

June 1, 2006

Primary Completion Date

April 1, 2009

Study Completion Date

October 1, 2011

Conditions

Bone Metastases

Interventions

BIOLOGICAL

Denosumab

120 milligrams by subcutaneous injection every 4 weeks

DRUG

Zoledronic Acid

4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00330759 - Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. | Biotech Hunter | Biotech Hunter